LLY Quote, Financials, Valuation and Earnings

Biogen has a net margin of 8.48% compared to Eli Lilly and's net margin of 15.76%. Eli Lilly and's return on equity of 66.4% beat Biogen's return on equity of 10.52%.

Eli Lilly and has a consensus price target of $978.39, signalling upside risk potential of 21.06%. On the other hand Biogen has an analysts' consensus of $230.67 which suggests that it could grow by 55.06%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Biogen has a beta of -0.071, suggesting its less volatile than the S&P 500 by 107.051%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.64%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Biogen quarterly revenues of $2.5B. Eli Lilly and's net income of $970.3M is higher than Biogen's net income of $388.5M. Notably, Eli Lilly and's price-to-earnings ratio is 87.37x while Biogen's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.88x versus 2.26x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 8.48% compared to Eli Lilly and's net margin of 0.7%. Eli Lilly and's return on equity of 66.4% beat Moderna's return on equity of -17.44%.

Eli Lilly and has a consensus price target of $978.39, signalling upside risk potential of 21.06%. On the other hand Moderna has an analysts' consensus of $66.73 which suggests that it could grow by 60.22%. Given that Moderna has higher upside potential than Eli Lilly and, analysts believe Moderna is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.64%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Moderna quarterly revenues of $1.9B. Eli Lilly and's net income of $970.3M is higher than Moderna's net income of $13M. Notably, Eli Lilly and's price-to-earnings ratio is 87.37x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.88x versus 3.19x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 8.48% compared to Eli Lilly and's net margin of --. Eli Lilly and's return on equity of 66.4% beat Viking Therapeutics's return on equity of --.

Eli Lilly and has a consensus price target of $978.39, signalling upside risk potential of 21.06%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 228.75%. Given that Viking Therapeutics has higher upside potential than Eli Lilly and, analysts believe Viking Therapeutics is more attractive than Eli Lilly and.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.64%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Viking Therapeutics quarterly revenues of --. Eli Lilly and's net income of $970.3M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Eli Lilly and's price-to-earnings ratio is 87.37x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.88x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 8.48% compared to Eli Lilly and's net margin of 37.71%. Eli Lilly and's return on equity of 66.4% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Eli Lilly and has a consensus price target of $978.39, signalling upside risk potential of 21.06%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.27 which suggests that it could grow by 10.23%. Given that Eli Lilly and has higher upside potential than Vertex Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Vertex Pharmaceuticals.

Eli Lilly and has a beta of 0.413, which suggesting that the stock is 58.729% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Eli Lilly and has a quarterly dividend of $1.30 per share corresponding to a yield of 0.64%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eli Lilly and pays 77.65% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Eli Lilly and quarterly revenues are $11.4B, which are larger than Vertex Pharmaceuticals quarterly revenues of $2.8B. Eli Lilly and's net income of $970.3M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Eli Lilly and's price-to-earnings ratio is 87.37x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eli Lilly and is 17.88x versus 10.87x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.